We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Jounce

News List

Jounce Therapeutics Receives FDA Clearance of Investigational NDA for Anti-CCR8 Antibody americanpharmaceuticalreview
June 17, 2021
Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. FDA's clearance of its Investigational New Drug (IND) application for JTX-1811 ...
Celgene licenses antibody JTX-8064 from Jounce for $50m pharmaceutical-technology
July 25, 2019
Global biopharma company Celgene has updated its 2016 strategic collaboration with clinical stage-focused Jounce Therapeutics and has decided to license global rights to JTX-8064; Celgene will now be responsible for all development and commercialisation o